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piastolic Dysfunction
s an Independent Risk
actor for Death in Patients
ith Sickle Cell Disease
e read with interest the study by Sachdev et al. (1) that identified
iastolic dysfunction as a poor prognostic factor in patients with
ickle cell disease.
Absolute serum creatinine in the study cohort may have
nderestimated the severity of kidney disease. The incidence of
enal insufficiency in a cohort of sickle cell patients has been found
o be 4% to 7% (2,3). Chronic kidney disease is known to be a
rognostic factor for worse cardiovascular outcomes (4). The
merican Kidney Foundation has proposed creatinine clearance as
better assessment of kidney function (5).
In addition, methadone use for sickle cell-related chronic pain
ncreases the risk of QT prolongation and torsades de pointes-
elated arrhythmic events (6,7).
Abnormal diastolic function may result from myocardial iron
verload (8). Myocardial iron overload has been reported in an
utopsy study of sickle cell patients (9). The use of validated
ardiovascular T2* magnetic resonance for early diagnosis of
yocardial iron overload demonstrated that myocardial iron con-
ent cannot be predicted from serum ferritin or liver iron (10).
Creatinine clearance, narcotic use, and myocardial iron overload
hould therefore be included in studies of mortality among sickle
ell patients.
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eply
e appreciate the important information presented by Dr. Ntim
nd colleagues in reference to our report on diastolic dysfunction in
ickle cell disease (SCD) patients. They suggest that renal insuf-
ciency in our cohort may have been underestimated by using
bsolute serum creatinine levels instead of creatinine clearance. We
ave found in our sickle cell patient cohort that absolute creatinine
evels correlate well with estimated creatinine clearance using the
odification of Diet in Renal Disease (MDRD) study equation
nd Cockgroft-Galt (CG) formulas (Spearman   0.91, p 
.0001 and   0.71, p  0.0001, respectively). Indeed, renal
isease characterized by any of these measures is an important risk
actor in the SCD population, and we reported in our initial study
1) that, “besides the tricuspid regurgitant jet velocity, the only
ignificant univariate correlate of the risk of death was the
reatinine level (p  0.007).” In the present study (2), we found a
ood correlation between the creatinine level and the E/A ratio
  0.46; p  0.0001); however, the E/A ratio remained
ignificantly associated with mortality after adjustment for log10
reatinine. Similarly, when we adjusted for the MDRD GFR and
G GFR, the E/A ratio remained significantly associated with
ortality (p  0.0001 and p  0.0002, respectively).
Although our study shows evidence of diastolic dysfunction in
he SCD population, the etiology of this is likely to be multifac-
orial and may include relative systemic hypertension, microvascu-
ar vaso-occlusive disease, and iron overload. The presence of iron
n the myocardium can be detected by advanced imaging tech-
iques, including tissue Doppler echocardiography (3) and mag-
etic resonance imaging (4). We certainly agree that more accurate
opulation-based measures of iron burden would be of great value
o this field of research.
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July 24, 2007:378–9Dr. Ntim and colleagues cite reports of narcotic use being
ssociated with prolonged QT and arrhythmic events. This is an
nteresting observation that requires follow-up, because the prox-
mate cause of death in many SCD patients remains unknown.
his being said, it is important to note that many of our patients
ith severe pulmonary hypertension and high hemolytic rate
anifest a low frequency of vaso-occlusive crisis and many rarely
se narcotics. This is consistent with the observation that patients
ith hemolytic anemia secondary to thalassemia and other hered-
tary hemolytic conditions develop pulmonary hypertension but do
ot have hemoglobin S or vaso-occlusive pain crises. We have
uggested a paradigm in which hemolytic anemia leads to distinct
omplications associated with low nitric oxide bioavailability and
asculopathy, including priapism, cutaneous leg ulcerations, sud-
en death, and pulmonary hypertension (5). In contrast, high
teady-state hemoglobin and leukocytosis are risk factors for
requency of vaso-occlusive pain crisis, acute chest syndrome, and
ncreased narcotic usage.
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